Clinical Trials Directory

Trials / Completed

CompletedNCT02818465

Role of the Interaction Between Advanced Glycation End Products and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients

Role of the Interaction Between AGEs and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
CHU de Reims · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Chronic kidney disease (CKD) is associated with an extensive vasculopathy and high cardiovascular mortality as well as an accumulation of uremic toxins. Among the latest, advanced glycation end-products (AGEs) interact with RAGE. Investigators aimed to analyze the role of RAGE in the calcification process of hemodialyzed patients, in a correlative and prospective study. Vascular calcifications will be assessed by Xray and tomodentimetry while accumulation of AGEs will be measured in the serum and in the skin (non invasive). Additionally factors influencing RAGE activation such as genetic polymorphism and level of soluble forms of RAGE will be measured and analyzed.

Conditions

Interventions

TypeNameDescription
OTHERVascular calcifications by Xray
OTHERVascular calcifications by tomodentimetry
BIOLOGICALBlood sample withdrawn

Timeline

Start date
2015-03-30
Primary completion
2017-11-16
Completion
2017-11-16
First posted
2016-06-29
Last updated
2026-01-21

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02818465. Inclusion in this directory is not an endorsement.